FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118769673> ?p ?o ?g. }

• W2118769673 endingPage "1110.e11" @default.
• W2118769673 startingPage "1103" @default.
• W2118769673 abstract "BackgroundAlthough studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued.ObjectiveWe sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both.MethodsThis was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU).ResultsFifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g “desensitization” OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008).ConclusionsIn this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU). Although studies of oral immunotherapy (OIT) for food allergy have shown promise, treatment is frequently complicated by adverse reactions and, even when successful, has limited long-term efficacy because benefits usually diminish when treatment is discontinued. We sought to examine whether the addition of omalizumab to milk OIT reduces treatment-related reactions, improves outcomes, or both. This was a double-blind, placebo-controlled trial with subjects randomized to omalizumab or placebo. Open-label milk OIT was initiated after 4 months of omalizumab/placebo with escalation to maintenance over 22 to 40 weeks, followed by daily maintenance dosing through month 28. At month 28, omalizumab was discontinued, and subjects passing an oral food challenge (OFC) continued OIT for 8 weeks, after which OIT was discontinued with rechallenge at month 32 to assess sustained unresponsiveness (SU). Fifty-seven subjects (7-32 years) were randomized, with no significant baseline differences in age, milk-specific IgE levels, skin test results, or OFC results. At month 28, 24 (88.9%) omalizumab-treated subjects and 20 (71.4%) placebo-treated subjects passed the 10-g “desensitization” OFC (P = .18). At month 32, SU was demonstrated in 48.1% in the omalizumab group and 35.7% in the placebo group (P = .42). Adverse reactions were markedly reduced during OIT escalation in omalizumab-treated subjects for percentages of doses per subject provoking symptoms (2.1% vs 16.1%, P = .0005), dose-related reactions requiring treatment (0.0% vs 3.8%, P = .0008), and doses required to achieve maintenance (198 vs 225, P = .008). In this first randomized, double-blind, placebo-controlled trial of omalizumab in combination with food OIT, we found significant improvements in measurements of safety but not in outcomes of efficacy (desensitization and SU)." @default.
• W2118769673 created "2016-06-24" @default.
• W2118769673 creator A5013895038 @default.
• W2118769673 creator A5015552885 @default.
• W2118769673 creator A5020080453 @default.
• W2118769673 creator A5023139523 @default.
• W2118769673 creator A5028760615 @default.
• W2118769673 creator A5045041188 @default.
• W2118769673 creator A5048600560 @default.
• W2118769673 creator A5072039777 @default.
• W2118769673 date "2016-04-01" @default.
• W2118769673 modified "2023-10-11" @default.
• W2118769673 title "A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy" @default.
• W2118769673 cites W1900907547 @default.
• W2118769673 cites W1963754158 @default.
• W2118769673 cites W1969953062 @default.
• W2118769673 cites W1971723752 @default.
• W2118769673 cites W1996237432 @default.
• W2118769673 cites W2008902704 @default.
• W2118769673 cites W2009608314 @default.
• W2118769673 cites W2013307032 @default.
• W2118769673 cites W2022764839 @default.
• W2118769673 cites W2026887388 @default.
• W2118769673 cites W2027046805 @default.
• W2118769673 cites W2028156173 @default.
• W2118769673 cites W2029386087 @default.
• W2118769673 cites W2031202979 @default.
• W2118769673 cites W2033224756 @default.
• W2118769673 cites W2033975621 @default.
• W2118769673 cites W2037507700 @default.
• W2118769673 cites W2050928602 @default.
• W2118769673 cites W2061228058 @default.
• W2118769673 cites W2065357866 @default.
• W2118769673 cites W2069780509 @default.
• W2118769673 cites W2070500245 @default.
• W2118769673 cites W2075056701 @default.
• W2118769673 cites W2091063781 @default.
• W2118769673 cites W2100042048 @default.
• W2118769673 cites W2101419854 @default.
• W2118769673 cites W2117748999 @default.
• W2118769673 cites W2123227703 @default.
• W2118769673 cites W2132083799 @default.
• W2118769673 cites W2146045461 @default.
• W2118769673 cites W2162344297 @default.
• W2118769673 cites W2166467474 @default.
• W2118769673 cites W4234374710 @default.
• W2118769673 doi "https://doi.org/10.1016/j.jaci.2015.10.005" @default.
• W2118769673 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5395304" @default.
• W2118769673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26581915" @default.
• W2118769673 hasPublicationYear "2016" @default.
• W2118769673 type Work @default.
• W2118769673 sameAs 2118769673 @default.
• W2118769673 citedByCount "267" @default.
• W2118769673 countsByYear W21187696732016 @default.
• W2118769673 countsByYear W21187696732017 @default.
• W2118769673 countsByYear W21187696732018 @default.
• W2118769673 countsByYear W21187696732019 @default.
• W2118769673 countsByYear W21187696732020 @default.
• W2118769673 countsByYear W21187696732021 @default.
• W2118769673 countsByYear W21187696732022 @default.
• W2118769673 countsByYear W21187696732023 @default.
• W2118769673 crossrefType "journal-article" @default.
• W2118769673 hasAuthorship W2118769673A5013895038 @default.
• W2118769673 hasAuthorship W2118769673A5015552885 @default.
• W2118769673 hasAuthorship W2118769673A5020080453 @default.
• W2118769673 hasAuthorship W2118769673A5023139523 @default.
• W2118769673 hasAuthorship W2118769673A5028760615 @default.
• W2118769673 hasAuthorship W2118769673A5045041188 @default.
• W2118769673 hasAuthorship W2118769673A5048600560 @default.
• W2118769673 hasAuthorship W2118769673A5072039777 @default.
• W2118769673 hasBestOaLocation W21187696731 @default.
• W2118769673 hasConcept C126322002 @default.
• W2118769673 hasConcept C141071460 @default.
• W2118769673 hasConcept C141105273 @default.
• W2118769673 hasConcept C142724271 @default.
• W2118769673 hasConcept C159654299 @default.
• W2118769673 hasConcept C168563851 @default.
• W2118769673 hasConcept C170493617 @default.
• W2118769673 hasConcept C197934379 @default.
• W2118769673 hasConcept C203014093 @default.
• W2118769673 hasConcept C204787440 @default.
• W2118769673 hasConcept C207480886 @default.
• W2118769673 hasConcept C27081682 @default.
• W2118769673 hasConcept C2776027960 @default.
• W2118769673 hasConcept C2776203516 @default.
• W2118769673 hasConcept C2777288759 @default.
• W2118769673 hasConcept C2778564945 @default.
• W2118769673 hasConcept C2779779143 @default.
• W2118769673 hasConcept C42219234 @default.
• W2118769673 hasConcept C71924100 @default.
• W2118769673 hasConceptScore W2118769673C126322002 @default.
• W2118769673 hasConceptScore W2118769673C141071460 @default.
• W2118769673 hasConceptScore W2118769673C141105273 @default.
• W2118769673 hasConceptScore W2118769673C142724271 @default.
• W2118769673 hasConceptScore W2118769673C159654299 @default.
• W2118769673 hasConceptScore W2118769673C168563851 @default.
• W2118769673 hasConceptScore W2118769673C170493617 @default.
• W2118769673 hasConceptScore W2118769673C197934379 @default.

• next